Announcement of protocol change in thrombolysis in myocardial infarction trial.
Announcement of protocol change in thrombolysis in myocardial infarction trial.
复制标题
心肌梗死试验中溶栓治疗方案变更的公告。
DOI:
10.1016/s0735-1097(87)80407-2
复制
发表时间:
1987
影响因子:
24
通讯作者:
T. Robertson
中科院分区:
文献类型:
--
作者:
E. Braunwald;G. Knatterud;E. Passamani;T. Robertson
The National Heart. Lung. and Blood Institute's Thrombolysis in Myocardial Infarction (TIMO Study has reduced the dose of tissue plasminogen activator (rt-PA) used from 150 mg over 6 hours to 100 mg over 6 hours. This protocol change was taken after review and recommendation by an independent Safety and Data Monitoring Committee. This recommendation was based in large part on the occurrence of intracerebral hemorrhage in 5 of 311 patients (1.6%) during a prerandomization pilot study. Three of these five events occurred within 24 hours of onset of treatment and three were fatal during hospitalization. Major hemorrhagic events defined as either intracerebral hemorrhage or a decline in hemoglobin of"" 5 g/dl were observed in 41 of 311 patients (13.2%), However, the overall in-hospital mortality in this series was 15of 311 (4.8%), Intracerebral hemorrhage occurred in only I of 386 patients treated with rt-PA in prior TIMI protocols. All TIMI patients received full dose heparin anticoagulation in addition to rt-PA infusion. The etiology of these intracerebral hemorrhages could be related to multiple factors including prior neurologic disease. Thrombolytic therapy should be given to individuals only after careful screening for contraindications such as prior neurologic events. serious hypertension and potential bleeding sites.